Institutional investors purchased a net $240.3 thousand shares of TARO during the quarter ended December 2012. This may signal that the smart money is gaining interest in this company as the 5.61% of the shares outstanding that institutional investors hold is among the lowest in the Pharmaceuticals: Generic industry.
| Other institutional | 5.37% |
| Individual stakeholders | 10.19% |
| Mutual fund holders | 0.24% |